Study on the effect and transformation of Azilsartan on improving microcirculation in hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073602

Enrollment

Unknown

Registered

2023-07-16

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Azilsartan Group:Daily oral administration of Azilsartan tablets 20mg

lifestly groups:lifestyle intervention

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Essential hypertension (diagnosis room blood pressure: systolic blood pressure 140-159 mmHg and/or diastolic blood pressure 90-99 mmHg, Conforming to the diagnostic criteria for level 1 hypertension in the Chinese Guidelines for the Prevention and Treatment of Hypertension (revised in 2018) 2. 18-60 years old; 3. I have not used any drugs or dietary supplements that affect blood pressure or endothelial function in the past three months, mainly including Including antihypertensive, lipid-lowering, hypoglycemic drugs, and natural plant extracts antioxidants; 4. After fully understanding the purpose and process of this study, disease characteristics, drug effects, and relevant examination methods And voluntarily sign an informed consent form after studying the potential risks/benefits

Exclusion criteria

Exclusion criteria: 1. There are secondary factors of elevated blood pressure; 2. Level 2 or above hypertension or level 1 hypertension has received medication treatment; 3. Drug allergy or intolerance; 4. Patients with serious heart disease, diabetes, abnormal liver and kidney functions (ALT is greater than the upper limit of normal value; eGFR<60mL/min/1.73m2), acute and chronic infections, autoimmune diseases and any history of cancer; 5. Diabetes patients who are taking aligilen fumarate; 6. Mental illness patients who are unable to cooperate; 7. Pregnant women, lactating women, or expectant pregnant women;

Design outcomes

Primary

Measure	Time frame
Fundus microvascular density;	—

Secondary

Measure	Time frame
No perfusion area;blood pressure;Blood biochemical indexes;liver and renal function;	—

Countries

China

Contacts

Public ContactXu Shiyue

The First Affiliated Hospital of Sun Yat-sen University

xsy279@163.com+86 139 2954 7207

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026